Zobrazeno 1 - 10
of 115
pro vyhledávání: '"Davida F Kruger"'
Publikováno v:
Clinical Diabetes. 41:198-207
Advances in insulin delivery technologies have led to the development of tubeless “patch” systems; however, these devices still involve a level of complexity. We surveyed individuals with type 1 or type 2 diabetes to explore their attitudes and s
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f7a706cf50f98e1b2b5fc5a38bc39850
https://doi.org/10.2337/cd22-0034
https://doi.org/10.2337/cd22-0034
Publikováno v:
ADCES in Practice. 10:20-25
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::4ee20ed998a473d265f64f16819affd8
https://doi.org/10.1177/2633559x221110216
https://doi.org/10.1177/2633559x221110216
Publikováno v:
Clin Diabetes
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::b5ec50d7a945c1c7aebf578025d04371
https://pubmed.ncbi.nlm.nih.gov/35983422
https://pubmed.ncbi.nlm.nih.gov/35983422
Autor:
Gregory P. Forlenza, Carol J. Levy, Rodolfo J. Galindo, Janet B. McGill, Guillermo E. Umpierrez, Anders L. Carlson, Christopher G. Parkin, Grazia Aleppo, Davida F. Kruger
Publikováno v:
Diabetes Technology & Therapeutics
Numerous studies have demonstrated the clinical value and safety of insulin pump therapy in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for insulin pump coverage required by the Centers for Medicare & Medicaid S
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::08b76c2adb9569654328ea0b462d2348
https://doi.org/10.1089/dia.2021.0196
https://doi.org/10.1089/dia.2021.0196
Autor:
William Biggs, Ian Orozco, Georgia Davis, Katrina J. Ruedy, Roy W. Beck, Janet B. McGill, Anuj Bhargava, Davida F. Kruger, Grazia Aleppo, William H. Polonsky, Quang T Nguyen, Laura A. Young, David Price, John B. Buse, Shichun Bao, Ryan Bailey, Peter Calhoun, Guillermo E. Umpierrez, Rodica Pop-Busui, Athena Philis-Tsimikas, K. Jean Lucas, Thomas W. Martens, Richard M. Bergenstal, Anne L. Peters
Publikováno v:
Diabetes Care
OBJECTIVE To explore the effect of discontinuing continuous glucose monitoring (CGM) after 8 months of CGM use in adults with type 2 diabetes treated with basal without bolus insulin. RESEARCH DESIGN AND METHODS This multicenter trial had an initial
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::e3177153afb2b86ac271d8ae64f6e6f1
https://doi.org/10.2337/dc21-1304
https://doi.org/10.2337/dc21-1304
Autor:
Christopher G. Parkin, Guillermo E. Umpierrez, Carol J. Levy, Grazia Aleppo, Davida F. Kruger, Janet B. McGill, Rodolfo J. Galindo, Anders L. Carlson
Publikováno v:
Diabetes Technology & Therapeutics
Numerous studies have demonstrated the clinical value of continuous glucose monitoring (CGM) in type 1 diabetes and type 2 diabetes populations. However, the eligibility criteria for CGM coverage required by the Centers for Medicare & Medicaid Servic
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2b0f93f280c6d825998dde97c4bb00b6
http://europepmc.org/articles/PMC8501458
http://europepmc.org/articles/PMC8501458
Autor:
Pamela R. Kushner, Davida F. Kruger
Publikováno v:
Clin Diabetes
Continuous glucose monitoring (CGM) provides comprehensive assessment of daily glucose measurements for patients with diabetes and can reveal high and low blood glucose values that may occur even when a patient’s A1C is adequately controlled. Among
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::23799da7f644bd6e1e17cdcb8c7f8e30
https://doi.org/10.2337/cd19-0093
https://doi.org/10.2337/cd19-0093
Autor:
Sherwin C D'Souza, Davida F. Kruger
Publikováno v:
Diabetes Therapy
With the availability of second-generation basal insulin analogs, insulin degludec (100 and 200 units/ml [degludec]) and insulin glargine 300 units/ml (glargine U300), clinicians now have long-acting, efficacious treatment options with stable pharmac
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5b50ab55ab1e52dc0e37c1d038a5e496
https://doi.org/10.1007/s13300-020-00920-z
https://doi.org/10.1007/s13300-020-00920-z
Autor:
Alandra Verdejo, Maria J. Redondo, Michael R. Rickels, Ashley M. Butler, Jeffrey S. Gonzalez, Judith A. Long, Shivani Agarwal, Robin L. Gal, Davida F. Kruger, Viral N. Shah, Steven M Willi, Ashby F. Walker, Lauren Kanapka, Jennifer K. Raymond, Andrea Gerard-Gonzalez
Publikováno v:
The Journal of Clinical Endocrinology and Metabolism
ContextMinority young adults (YA) currently represent the largest growing population with type 1 diabetes (T1D) and experience very poor outcomes. Modifiable drivers of disparities need to be identified, but are not well-studied.ObjectiveTo describe
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d33a7073b04ca46ad5d030596dd9cdb2
https://doi.org/10.1210/clinem/dgaa236
https://doi.org/10.1210/clinem/dgaa236
Publikováno v:
Diabetes Technology & Therapeutics
Despite ongoing advances in medications, insulin delivery systems, and glucose monitoring technologies, diabetes control remains suboptimal in many individuals with this disease.1 In addition to the clinical consequences resulting from poor control i
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::aa3ef3ea0da4211a08f6dddc7b0849cf
https://doi.org/10.1089/dia.2019.0303
https://doi.org/10.1089/dia.2019.0303